Cargando…

DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers

BACKGROUND: Understanding how aberrant transcription factors (TFs) hijack normal development to induce oncogenesis is a critical question in oncology. Forkhead box (FOX) proteins are a superfamily of transcriptional regulators characterized by a forkhead DNA-binding domain. Within this family, Forkh...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Jessica W, Cejas, Paloma, Wang, Dayle K, Patel, Smruti, Wu, David W, Arounleut, Phonepasong, Wei, Xin, Zhou, Ningxuan, Syamala, Sudeepa, Dubois, Frank P B, Crane, Alexander, Pelton, Kristine, Vogelzang, Jayne, Sousa, Cecilia, Baguette, Audrey, Chen, Xiaolong, Condurat, Alexandra L, Dixon-Clarke, Sarah E, Zhou, Kevin N, Lu, Sophie D, Gonzalez, Elizabeth M, Chacon, Madison S, Digiacomo, Jeromy J, Kumbhani, Rushil, Novikov, Dana, Hunter, J'Ya, Tsoli, Maria, Ziegler, David S, Dirksen, Uta, Jager, Natalie, Balasubramanian, Gnana Prakash, Kramm, Christof M, Nathrath, Michaela, Bielack, Stefan, Baker, Suzanne J, Zhang, Jinghui, McFarland, James M, Getz, Gad, Aguet, Francois, Jabado, Nada, Witt, Olaf, Pfister, Stefan M, Ligon, Keith L, Kleinman, Claudia L, Long, Henry, Jones, David T W, Bandopadhayay, Pratiti, Phoenix, Timothy N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165142/
http://dx.doi.org/10.1093/neuonc/noac079.076
_version_ 1784720319124078592
author Tsai, Jessica W
Cejas, Paloma
Wang, Dayle K
Patel, Smruti
Wu, David W
Arounleut, Phonepasong
Wei, Xin
Zhou, Ningxuan
Syamala, Sudeepa
Dubois, Frank P B
Crane, Alexander
Pelton, Kristine
Vogelzang, Jayne
Sousa, Cecilia
Baguette, Audrey
Chen, Xiaolong
Condurat, Alexandra L
Dixon-Clarke, Sarah E
Zhou, Kevin N
Lu, Sophie D
Gonzalez, Elizabeth M
Chacon, Madison S
Digiacomo, Jeromy J
Kumbhani, Rushil
Novikov, Dana
Hunter, J'Ya
Tsoli, Maria
Ziegler, David S
Dirksen, Uta
Jager, Natalie
Balasubramanian, Gnana Prakash
Kramm, Christof M
Nathrath, Michaela
Bielack, Stefan
Baker, Suzanne J
Zhang, Jinghui
McFarland, James M
Getz, Gad
Aguet, Francois
Jabado, Nada
Witt, Olaf
Pfister, Stefan M
Ligon, Keith L
Kleinman, Claudia L
Long, Henry
Jones, David T W
Bandopadhayay, Pratiti
Phoenix, Timothy N
author_facet Tsai, Jessica W
Cejas, Paloma
Wang, Dayle K
Patel, Smruti
Wu, David W
Arounleut, Phonepasong
Wei, Xin
Zhou, Ningxuan
Syamala, Sudeepa
Dubois, Frank P B
Crane, Alexander
Pelton, Kristine
Vogelzang, Jayne
Sousa, Cecilia
Baguette, Audrey
Chen, Xiaolong
Condurat, Alexandra L
Dixon-Clarke, Sarah E
Zhou, Kevin N
Lu, Sophie D
Gonzalez, Elizabeth M
Chacon, Madison S
Digiacomo, Jeromy J
Kumbhani, Rushil
Novikov, Dana
Hunter, J'Ya
Tsoli, Maria
Ziegler, David S
Dirksen, Uta
Jager, Natalie
Balasubramanian, Gnana Prakash
Kramm, Christof M
Nathrath, Michaela
Bielack, Stefan
Baker, Suzanne J
Zhang, Jinghui
McFarland, James M
Getz, Gad
Aguet, Francois
Jabado, Nada
Witt, Olaf
Pfister, Stefan M
Ligon, Keith L
Kleinman, Claudia L
Long, Henry
Jones, David T W
Bandopadhayay, Pratiti
Phoenix, Timothy N
author_sort Tsai, Jessica W
collection PubMed
description BACKGROUND: Understanding how aberrant transcription factors (TFs) hijack normal development to induce oncogenesis is a critical question in oncology. Forkhead box (FOX) proteins are a superfamily of transcriptional regulators characterized by a forkhead DNA-binding domain. Within this family, Forkhead Box R2 (FOXR2) has been identified as a candidate structural variant (SV) driver in a subset of pediatric cancers including CNS embryonal tumors and peripheral neuroblastoma. While FOXR2 has been shown to stabilize MYC isoforms, the mechanistic details through which it enhances tumor formation, other non-SV mechanisms of activating aberrant expression, and the true extent of its role as an oncogene across all cancers have not been systematically evaluated. METHODS: We applied an integrative approach using transcriptomics, epigenetics, in vitro cancer models, and in vivo mouse models to systematically evaluate the mechanisms by which FOXR2 is activated across human cancers. RESULTS: We performed a pan-cancer analysis of FOXR2 activation across over 10,000 adult and pediatric cancer samples, and surprisingly found FOXR2 to be aberrantly upregulated in 70% of all cancer types (including diffuse midline gliomas), and 8% of all individual tumors. FOXR2 expression occurred predominantly in the absence of rearrangement/fusions, single nucleotide variants, or copy number aberrations at the DNA level. Transcriptomic and epigenomic analyses show the vast majority of tumors (78%) aberrantly express FOXR2 through a previously undescribed epigenetic mechanism via hypomethylation of a novel promoter. Using both in vitro and in vivo models, we demonstrate that FOXR2 expression is both sufficient and necessary for transformation across multiple lineages, including DMGs. CONCLUSION: Taken together, this study demonstrates that FOXR2 is a novel and potent oncogene across pediatric and adult cancers, and highlights a new epigenetic mechanism by which its expression is activated.
format Online
Article
Text
id pubmed-9165142
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91651422022-06-05 DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers Tsai, Jessica W Cejas, Paloma Wang, Dayle K Patel, Smruti Wu, David W Arounleut, Phonepasong Wei, Xin Zhou, Ningxuan Syamala, Sudeepa Dubois, Frank P B Crane, Alexander Pelton, Kristine Vogelzang, Jayne Sousa, Cecilia Baguette, Audrey Chen, Xiaolong Condurat, Alexandra L Dixon-Clarke, Sarah E Zhou, Kevin N Lu, Sophie D Gonzalez, Elizabeth M Chacon, Madison S Digiacomo, Jeromy J Kumbhani, Rushil Novikov, Dana Hunter, J'Ya Tsoli, Maria Ziegler, David S Dirksen, Uta Jager, Natalie Balasubramanian, Gnana Prakash Kramm, Christof M Nathrath, Michaela Bielack, Stefan Baker, Suzanne J Zhang, Jinghui McFarland, James M Getz, Gad Aguet, Francois Jabado, Nada Witt, Olaf Pfister, Stefan M Ligon, Keith L Kleinman, Claudia L Long, Henry Jones, David T W Bandopadhayay, Pratiti Phoenix, Timothy N Neuro Oncol Diffuse Midline Glioma/DIPG BACKGROUND: Understanding how aberrant transcription factors (TFs) hijack normal development to induce oncogenesis is a critical question in oncology. Forkhead box (FOX) proteins are a superfamily of transcriptional regulators characterized by a forkhead DNA-binding domain. Within this family, Forkhead Box R2 (FOXR2) has been identified as a candidate structural variant (SV) driver in a subset of pediatric cancers including CNS embryonal tumors and peripheral neuroblastoma. While FOXR2 has been shown to stabilize MYC isoforms, the mechanistic details through which it enhances tumor formation, other non-SV mechanisms of activating aberrant expression, and the true extent of its role as an oncogene across all cancers have not been systematically evaluated. METHODS: We applied an integrative approach using transcriptomics, epigenetics, in vitro cancer models, and in vivo mouse models to systematically evaluate the mechanisms by which FOXR2 is activated across human cancers. RESULTS: We performed a pan-cancer analysis of FOXR2 activation across over 10,000 adult and pediatric cancer samples, and surprisingly found FOXR2 to be aberrantly upregulated in 70% of all cancer types (including diffuse midline gliomas), and 8% of all individual tumors. FOXR2 expression occurred predominantly in the absence of rearrangement/fusions, single nucleotide variants, or copy number aberrations at the DNA level. Transcriptomic and epigenomic analyses show the vast majority of tumors (78%) aberrantly express FOXR2 through a previously undescribed epigenetic mechanism via hypomethylation of a novel promoter. Using both in vitro and in vivo models, we demonstrate that FOXR2 expression is both sufficient and necessary for transformation across multiple lineages, including DMGs. CONCLUSION: Taken together, this study demonstrates that FOXR2 is a novel and potent oncogene across pediatric and adult cancers, and highlights a new epigenetic mechanism by which its expression is activated. Oxford University Press 2022-06-03 /pmc/articles/PMC9165142/ http://dx.doi.org/10.1093/neuonc/noac079.076 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Diffuse Midline Glioma/DIPG
Tsai, Jessica W
Cejas, Paloma
Wang, Dayle K
Patel, Smruti
Wu, David W
Arounleut, Phonepasong
Wei, Xin
Zhou, Ningxuan
Syamala, Sudeepa
Dubois, Frank P B
Crane, Alexander
Pelton, Kristine
Vogelzang, Jayne
Sousa, Cecilia
Baguette, Audrey
Chen, Xiaolong
Condurat, Alexandra L
Dixon-Clarke, Sarah E
Zhou, Kevin N
Lu, Sophie D
Gonzalez, Elizabeth M
Chacon, Madison S
Digiacomo, Jeromy J
Kumbhani, Rushil
Novikov, Dana
Hunter, J'Ya
Tsoli, Maria
Ziegler, David S
Dirksen, Uta
Jager, Natalie
Balasubramanian, Gnana Prakash
Kramm, Christof M
Nathrath, Michaela
Bielack, Stefan
Baker, Suzanne J
Zhang, Jinghui
McFarland, James M
Getz, Gad
Aguet, Francois
Jabado, Nada
Witt, Olaf
Pfister, Stefan M
Ligon, Keith L
Kleinman, Claudia L
Long, Henry
Jones, David T W
Bandopadhayay, Pratiti
Phoenix, Timothy N
DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers
title DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers
title_full DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers
title_fullStr DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers
title_full_unstemmed DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers
title_short DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers
title_sort dipg-19. foxr2 is an oncogenic driver across pediatric and adult cancers
topic Diffuse Midline Glioma/DIPG
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165142/
http://dx.doi.org/10.1093/neuonc/noac079.076
work_keys_str_mv AT tsaijessicaw dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT cejaspaloma dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT wangdaylek dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT patelsmruti dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT wudavidw dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT arounleutphonepasong dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT weixin dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT zhouningxuan dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT syamalasudeepa dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT duboisfrankpb dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT cranealexander dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT peltonkristine dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT vogelzangjayne dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT sousacecilia dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT baguetteaudrey dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT chenxiaolong dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT conduratalexandral dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT dixonclarkesarahe dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT zhoukevinn dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT lusophied dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT gonzalezelizabethm dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT chaconmadisons dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT digiacomojeromyj dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT kumbhanirushil dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT novikovdana dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT hunterjya dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT tsolimaria dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT zieglerdavids dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT dirksenuta dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT jagernatalie dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT balasubramaniangnanaprakash dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT krammchristofm dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT nathrathmichaela dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT bielackstefan dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT bakersuzannej dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT zhangjinghui dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT mcfarlandjamesm dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT getzgad dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT aguetfrancois dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT jabadonada dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT wittolaf dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT pfisterstefanm dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT ligonkeithl dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT kleinmanclaudial dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT longhenry dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT jonesdavidtw dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT bandopadhayaypratiti dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers
AT phoenixtimothyn dipg19foxr2isanoncogenicdriveracrosspediatricandadultcancers